Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

refractory hairy cell leukemia

Known as: Hairy Cell Leukemia, Refractory, leukemia, hairy cell, recurrent, recurrent hairy cell leukemia 
Hairy cell leukemia that is resistant to treatment.
National Institutes of Health

Related topics

Related topics

18 relations
Atypical lymphocyteB lymphoblastB-LymphocytesBRAF gene
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
PURPOSE To determine tolerability and for the first time explore efficacy of bendamustine-rituximab (BR) in multiply relapsed… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Immunotoxins are potent anticancer agents with an unusual mechanism of action: inhibition of protein synthesis resulting in… Expand
Is this relevant?
2013
2013
Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis
Dear Editor, Hairy-cell leukemia (HCL) is a rare hematological malignancy, which typically responds very well to first-line… Expand
  • figure 1
Is this relevant?
2013
2013
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
 
Is this relevant?
2012
2012
Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.
The purine analogs, pentostatin and cladribine, induce high remission rates when used as first-line monotherapy for hairy cell… Expand
  • figure 1
Is this relevant?
Review
2011
Review
2011
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Recombinant immunotoxins are fusion proteins that contain the cytotoxic portion of a protein toxin fused to the Fv portion of an… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
2008
2008
Effective Treatment of a Refractory Hairy Cell Leukemia Variant with Splenic Pre-Irradiation and Alemtuzumab
A 72-year-old Japanese man presented with 43.1 × 109/l hairy cells and apparent splenomegaly. The leukemia cells had unevenly… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2006
Review
2006
Immunotoxins in the treatment of refractory hairy cell leukemia.
An increasing number of patients who have hairy cell leukemia (HCL) have persistent disease that requires treatment, despite… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Rituximab in relapsed or refractory hairy cell leukemia.
The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody, rituximab, in relapsed or… Expand
  • table 1
  • table 2
  • table 4
  • table 3
  • figure 1
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
We report major responses in 4 of 4 patients with hairy cell leukemia (HCL) who have recently been treated on a phase I trial… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE